A physician and scientist and leading biopharmaceutical executive with board level experience, Dr. Lin was the first chief scientific officer and head of research and development at Horizon Therapeutics, a global biopharmaceutical company targeting medicines for rare diseases, rheumatology and primary care. At Horizon, she helped drive the transformation of Horizon from specialty to biopharma which contributed to more than tripling of the company’s market cap within two years in part by gaining the first FDA approval of a treatment for the vision threatening autoimmune condition, thyroid eye disease
Throughout her career, including her previous roles as a corporate officer at AbbVie leading therapeutic areas, development excellence, and international development, VP at Gilead, and in roles of increasing responsibility at Amgen, Dr. Lin has worked on rapidly developing life-changing medicines, including a cure for Hepatitis C
A strong advocate for medical innovation, culture transformation, building diverse teams, and creativity in medicine as well as work-life balance, Dr. Lin is a sought-after speaker. She has led discussion at the Aspen Ideas Festival and been recognized by PharmaVOICE as one of its “Most Inspiring People.”
Dr. Lin is magna cum laude graduate of Rice University in chemical engineering and biochemistry and holds an M.D. and Ph.D. from the Johns Hopkins University School of Medicine. She was on faculty as Clinical Scholar and associate physician at The Rockefeller University prior to joining industry and has also been adjunct faculty in medicine at UCLA, Stanford, and Northwestern.
She serves on the boards of Principia Biopharma and Lake Forest College.